(S)-CR8
| Code | Size | Price |
|---|
| AG-MR-C0004-M010 | 10 mg | £245.00 |
Quantity:
| AG-MR-C0004-M050 | 50 mg | £685.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
2-(S)-(1-Ethyl-2-hydroxyethylamino)-6-(4-(2-pyridyl)benzyl)-9-isopropylpurine
Appearance:
White to off-white solid.
CAS:
1084893-56-0
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Keep under inert gas.Protect from light.
Hazards:
H302
InChi:
InChI=1S/C24H29N7O/c1-4-19(14-32)28-24-29-22(21-23(30-24)31(15-27-21)16(2)3)26-13-17-8-10-18(11-9-17)20-7-5-6-12-25-20/h5-12,15-16,19,32H,4,13-14H2,1-3H3,(H2,26,28,29,30)/t19-/m0/s1
InChiKey:
HOCBJBNQIQQQGT-IBGZPJMESA-N
Long Description:
Chemical. CAS: 1084893-56-0. Formula: C24H29N7O. MW: 431.5. Potent cyclin-dependent kinase (CDK) 1, 2, 5, and 9 inhibitor. Apoptosis inducer. Inhibits the proliferation of various cancer cell lines. Inhibits cysts formation in culture. Casein kinase 1 (CK1delta/epsilon) and Dyrk1A inhibitor. Down regulates expression of Mcl-1 and MYCN. Neuroprotective in experimental traumatic brain injury. Potential anti-inflammatory compound. Potential antidiabetic compound.
MDL:
MFCD23160354
Molecular Formula:
C24H29N7O
Molecular Weight:
431.5
Package Type:
Vial
Precautions:
P264, P301, P312, P330
Product Description:
Potent cyclin-dependent kinase (CDK) 1, 2, 5, and 9 inhibitor [1, 2]. Apoptosis inducer [1, 3, 5]. Inhibits the proliferation of various cancer cell lines [1]. Inhibits cysts formation in culture [4]. Casein kinase 1 (CK1delta/epsilon) and Dyrk1A inhibitor [1]. Down regulates expression of Mcl-1 and MYCN. Neuroprotective in experimental traumatic brain injury. Potential anti-inflammatory compound. Potential antidiabetic compound.
Purity:
>99% (NMR)
Signal word:
Warning
SMILES:
CC[C@@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=C(C=C2)C2=NC=CC=C2)=N1
Solubility Chemicals:
Soluble in DMSO or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases: K. Bettayeb, et al.; Oncogene 27, 5797 (2008) | Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1: N. Oumata, et al.; J. Med. Chem. 51, 5229 (2008) | CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells: K. Bettayeb, et al.; Genes Cancer 1, 369 (2010) | CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD: N.O. Bukanov, et al.; Cell Cycle 11, 4040 (2012) | CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury. S.V. Kabadi, et al.; Neurotherapeutics 9, 405 (2012) | Inhibition of NF-kappaB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells: E. Cosimo, et al.; Clin. Cancer Res. 19, 2393 (2013)
Related Products
| Product Name | Product Code | Supplier | (R)-Roscovitine | AG-CR1-0006 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (R)-CR8 | AG-CR1-0039 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (R)-CR8 | AG-MR-C0003 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||